A meta-analysis explored the individual components of cognitive behavioral therapy for insomnia (CBT-I) and suggested that cognitive restructuring, stimulus control and sleep restrictions provide the more benefits to patients.
While tirzepatide has bagged FDA approval for treating T2D and for weight loss, the critical question remains can it also safeguard the kidneys, a key objective in diabetes care?